Gene reprogramming in exercise-induced cardiac hypertrophy in swine: A transcriptional genomics approach

Journal of Molecular and Cellular Cardiology

Volumn 77, Issue , 2014, Pages 168-174

  Kuster, Diederik W D ^a,b,c   Merkus, Daphne ^a   Blonden, Lau A ^a   Kremer, Andreas ^b   van IJcken, Wilfred F J ^b   Verhoeven, Adrie J M ^a,b   Duncker, Dirk J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal models of human disease; Cardiac hypertrophy; Exercise training; Microarray; Physiological hypertrophy; Transcription factors

Indexed keywords

GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR YY1; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BODY WEIGHT; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; EXERCISE; FEMALE; GENE EXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN MICROARRAY; SITTING; SWINE; UPREGULATION; ANIMAL; CARDIOMEGALY; DNA SEQUENCE; GENETIC EPIGENESIS; GENETICS; GENOMICS; HEART VENTRICLE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PIG; RUNNING;

ANIMALIA; SUIDAE;

ANIMALS; BINDING SITES; CARDIOMEGALY; EPIGENESIS, GENETIC; FEMALE; GENOMICS; HEART VENTRICLES; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHYSICAL CONDITIONING, ANIMAL; RUNNING; SEQUENCE ANALYSIS, DNA; SUS SCROFA; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84911429231     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.10.006     Document Type: Article

References (42)

1. Katz A.M. The "modern" view of heart failure: how did we get here?. Circ Heart Fail May 2008, 1(1):63-71.
2. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation Jun 27 2000, 101(25):2981-2988.
3. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med May 31 1990, 322(22):1561-1566.
4. White H.D., Norris R.M., Brown M.A., Brandt P.W., Whitlock R.M., Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation Jul 1987, 76(1):44-51.
5. Gielen S., Schuler G., Hambrecht R. Exercise training in coronary artery disease and coronary vasomotion. Circulation Jan 2 2001, 103(1):E1-E6.
6. Maron B.J., Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation Oct 10 2006, 114(15):1633-1644.
7. Bernardo B.C., Weeks K.L., Pretorius L., McMullen J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther Oct 2010, 128(1):191-227.
8. Beisvag V., Kemi O.J., Arbo I., Loennechen J.P., Wisloff U., Langaas M., et al. Pathological and physiological hypertrophies are regulated by distinct gene programs. Eur J Cardiovasc Prev Rehabil Dec 2009, 16(6):690-697.
9. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65:45-79.
10. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Kang P.M., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A Oct 14 2003, 100(21):12355-12360.
11. Galindo C.L., Skinner M.A., Errami M., Olson L.D., Watson D.A., Li J., et al. Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure. BMC Physiol 2009, 9:23.
12. Kong S.W., Bodyak N., Yue P., Liu Z., Brown J., Izumo S., et al. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics Mar 21 2005, 21(1):34-42.
13. Strom C.C., Aplin M., Ploug T., Christoffersen T.E., Langfort J., Viese M., et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J Jun 2005, 272(11):2684-2695.
14. Dixon J.A., Spinale F.G. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail May 2009, 2(3):262-271.
15. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res Jul 1998, 39(1):60-76.
16. Laughlin M.H., Hale C.C., Novela L., Gute D., Hamilton N., Ianuzzo C.D. Biochemical characterization of exercise-trained porcine myocardium. J Appl Physiol Jul 1991, 71(1):229-235.
17. White F.C., McKirnan M.D., Breisch E.A., Guth B.D., Liu Y.M., Bloor C.M. Adaptation of the left ventricle to exercise-induced hypertrophy. J Appl Physiol Mar 1987, 62(3):1097-1110.
18. Laughlin MH, Bowles DK, Duncker DJ. The coronary circulation in exercise training. American Journal of Physiology. Jan 1; 302(1): H10-23.
19. Kuster D.W., Merkus D., Kremer A., van Ijcken W.F., de Beer V.J., Verhoeven A.J., et al. Left ventricular remodeling in swine after myocardial infarction: a transcriptional genomics approach. Basic Res Cardiol Nov 2011, 106(6):1269-1281.
20. Duncker D.J., Boontje N.M., Merkus D., Versteilen A., Krysiak J., Mearini G., et al. Prevention of myofilament dysfunction by beta-blocker therapy in postinfarct remodeling. Circ Heart Fail May 2009, 2(3):233-242.
21. van der Velden J., Merkus D., Klarenbeek B.R., James A.T., Boontje N.M., Dekkers D.H., et al. Alterations in myofilament function contribute to left ventricular dysfunction in pigs early after myocardial infarction. Circ Res Nov 26 2004, 95(11):e85-e95.
22. van Kats J.P., Duncker D.J., Haitsma D.B., Schuijt M.P., Niebuur R., Stubenitsky R., et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation Sep 26 2000, 102(13):1556-1563.
23. Couture O., Callenberg K., Koul N., Pandit S., Younes R., Hu Z.L., et al. ANEXdb: an integrated animal ANnotation and microarray EXpression database. Mamm Genome Nov-Dec 2009, 20(11-12):768-777.
24. Kuster D.W., Merkus D., Jorna H.J., Dekkers D.H., Duncker D.J., Verhoeven A.J. Nuclear protein extraction from frozen porcine myocardium. J Physiol Biochem Jun 2011, 67(2):165-173.
25. Vara D., Bicknell K.A., Coxon C.H., Brooks G. Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy. J Biol Chem Jun 13 2003, 278(24):21388-21394.
26. Xiao G., Mao S., Baumgarten G., Serrano J., Jordan M.C., Roos K.P., et al. Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res Dec 7 2001, 89(12):1122-1129.
27. Lim J.Y., Park S.J., Hwang H.Y., Park E.J., Nam J.H., Kim J., et al. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol Oct 2005, 39(4):627-636.
28. Okamoto Y., Chaves A., Chen J., Kelley R., Jones K., Weed H.G., et al. Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction. Am J Pathol Aug 2001, 159(2):639-650.
29. Ferdous A., Battiprolu P.K., Ni Y.G., Rothermel B.A., Hill J.A. FoxO, autophagy, and cardiac remodeling. J Cardiovasc Transl Res Aug 2010, 3(4):355-364.
30. Veljkovic J., Hansen U. Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene Dec 8 2004, 343(1):23-40.
31. Pontoglio M., Barra J., Hadchouel M., Doyen A., Kress C., Bach J.P., et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell Feb 23 1996, 84(4):575-585.
32. Sucharov C.C., Mariner P., Long C., Bristow M., Leinwand L. Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter. J Biol Chem Aug 15 2003, 278(33):31233-31239.
33. Sucharov C.C., Dockstader K., McKinsey T.A. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell Oct 2008, 19(10):4141-4153.
34. Hickson R.C., Galassi T.M., Kurowski T.T., Daniels D.G., Chatterton R.T. Androgen and glucocorticoid mechanisms in exercise-induced cardiac hypertrophy. Am J Physiol Jun 1984, 246(6 Pt 2):H761-H767.
35. Chattopadhyay S., Gong E.Y., Hwang M., Park E., Lee H.J., Hong C.Y., et al. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells. Mol Endocrinol May 2006, 20(5):984-995.
36. Chun S.Y., Chen F., Washburn J.G., MacDonald J.W., Innes K.L., Zhao R., et al. CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3. Oncogene Jul 12 2007, 26(32):4725-4729.
37. Mann J.J., Payne J.R., Shah T., Pennell D.J., Humphries S.E., Montgomery H.E. C-reactive protein gene variant and the human left ventricular growth response to exercise: data from The LARGE Heart Study. J Cardiovasc Pharmacol Jan 2010, 55(1):26-29.
38. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell Jul 29 2005, 122(2):261-273.
39. DeBosch B., Treskov I., Lupu T.S., Weinheimer C., Kovacs A., Courtois M., et al. Akt1 is required for physiological cardiac growth. Circulation May 2 2006, 113(17):2097-2104.
40. Zhong W., Mao S., Tobis S., Angelis E., Jordan M.C., Roos K.P., et al. Hypertrophic growth in cardiac myocytes is mediated by Myc through a cyclin D2-dependent pathway. EMBO J Aug 23 2006, 25(16):3869-3879.
41. Hamdani N., de Waard M., Messer A.E., Boontje N.M., Kooij V., van Dijk S., et al. Myofilament dysfunction in cardiac disease from mice to men. J Muscle Res Cell Motil 2008, 29(6-8):189-201.
42. Haghighi K., Kolokathis F., Pater L., Lynch R.A., Asahi M., Gramolini A.O., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest Mar 2003, 111(6):869-876.